The adjusted mean number of new or enlarged gadolinium contrast-enhancing lesions was 4.75 in the interferon beta and placebo group compared with 1.32 in the interferon beta and high-dose daclizumab group ( difference 72 % , 95 % CI 34 % to 88 % ; p = 0.004 ) and 3.58 in the interferon beta and low-dose daclizumab group ( 25 % , -76 % to 68 % ; p = 0.51 ) .
